Vydura (rimegepant)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- rimegepant
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Migraine Disorders
- CHMP opinion
- Thu 24 Feb 2022
- EU approval
- Mon 25 Apr 2022
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005725
- ATC
- N02CD06
- Official record
- www.ema.europa.eu
Indication
Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
Regulatory milestones
No milestones recorded in the last year.
Follow Vydura
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.